AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Voglitum-Trio 0.3 Tablet ER

Prescription Icon
Prescription Required

Marketer

Advance Concept Pharmaceuticals Pvt. Ltd.

Salt Composition

Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)

Overview Voglitum-Trio 0.3 Tablet ER

Tridin-Met 0.3 Extended-Release tablets are classified as antidiabetic agents. This combination medication manages type 2 diabetes in adults by regulating blood glucose. Administer Tridin-Met 0.3 ER with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continue this medication as prescribed, even with controlled blood sugar, as discontinuation without consulting your doctor can elevate blood glucose, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan encompassing diet, exercise, and weight management as advised by your doctor; lifestyle choices are crucial for diabetes control. Hypoglycemia (low blood sugar) is the most common adverse effect. Learn to recognize hypoglycemic symptoms—sweating, dizziness, headache, tremors—and how to treat them. Maintain regular mealtimes and carry a fast-acting glucose source (e.g., sugary snacks, fruit juice). Alcohol increases hypoglycemia risk and should be avoided. Additional potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, or severe kidney/liver disease. Inform your doctor of any history of heart disease before commencing treatment; it may be unsuitable. Pregnant or lactating individuals should consult their physician before use. Regular blood glucose monitoring is essential, and your doctor might order blood tests to assess blood cell counts and liver function.

Uses of Voglitum-Trio 0.3 Tablet ER

Managing type 2 diabetes

Major Benefits of Voglitum-Trio 0.3 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the Voglitum-Trio 0.3 Tablet ER whole; avoid chewing, crushing, or breaking it. Administer on an empty stomach.

Common Side effects of Voglitum-Trio 0.3 Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Voglitum-Trio 0.3 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment period. Ingest the entire tablet without chewing, crushing, or breaking it. Voglitum-Trio 0.3 Tablet ER should be administered on an empty stomach.

How Voglitum-Trio 0.3 Tablet ER works:

Extended-release Voglitum-Trio 0.3mg tablets contain a triple-action antidiabetic formulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Voglitum-Trio 0.3 Tablet ER and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Voglitum-Trio 0.3 mg tablets might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Voglitum-Trio 0.3 mg tablets may pose a risk to breastfeeding infants. Available evidence indicates potential transfer to breast milk, posing a possible threat to the nursing child.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Extended-release Voglitum-Trio 0.3 mg tablets are likely unsafe for individuals with kidney impairment and should be avoided. Medical advice is recommended. Furthermore, this medication is not advised for patients experiencing severe kidney dysfunction.

LiverLiverCAUTION

Patients with liver impairment should use Voglitum-Trio 0.3 Tablet ER cautiously, potentially requiring dose modification. A physician's consultation is advised. Initial treatment with Voglitum-Trio 0.3 Tablet ER in patients exhibiting mild to moderate hepatic dysfunction typically begins with a reduced dosage; it's contraindicated in those with severe liver disease.

What if you forget to take Voglitum-Trio 0.3 Tablet ER :

Should you forget a dose of Voglitum-Trio 0.3 Tablet ER, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Voglitum-Trio 0.3 Tablet ER

LabelValue
Addictive None.
Medication Classification Medication for diabetes

FAQs on Voglitum-Trio 0.3 Tablet ER

Voglitum-Trio 0.3 Extended-Release tablets contain glimepiride, metformin, and voglibose. This triple-drug therapy manages type 2 diabetes mellitus by improving glycemic control in adults when combined with a healthy diet and regular physical activity. Glimepiride stimulates insulin secretion from the pancreas, reducing blood glucose. Metformin decreases hepatic glucose production and enhances insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, reduces post-meal blood sugar elevations. This formulation is unsuitable for treating type 1 diabetes.
Patients taking Voglitum-Trio 0.3 Extended-Release Tablets may experience side effects including low blood glucose, queasiness, loose stools, taste disturbances, gas, abdominal discomfort, cephalalgia, dermatological reactions, and upper respiratory infections.
Patients with hypersensitivity to Voglitum-Trio 0.3 Tablet ER's constituents or inactive ingredients should not use this extended-release tablet. Furthermore, its administration is contraindicated in individuals with moderate to severe nephropathy, inflammatory bowel disorders, colonic ulcers, and underlying metabolic acidosis, encompassing diabetic ketoacidosis.
Combining Voglitum-Trio 0.3 ER tablets and alcohol is unsafe. This combination can lead to dangerously low blood sugar and a heightened risk of lactic acidosis.
Indeed, Voglitum-Trio 0.3 Extended-Release tablets can induce hypoglycemia. Low blood sugar may manifest as nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremor. The risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. A readily available supply of glucose tablets, honey, or fruit juice is recommended.
Retain this medication within its original, sealed packaging. Follow the storage guidelines provided on the package or label. Discard any leftover medication. Prevent accidental ingestion by children, pets, and others.
Voglitum-Trio 0.3 Tablet ...
147
MRP 179
17% off